BDTX
NASDAQ · Biotechnology
Black Diamond Therapeutics I
$1.85
+0.10 (+5.71%)
Open$1.77
Previous Close$1.75
Day High$1.88
Day Low$1.75
52W High$4.94
52W Low$1.60
Volume—
Avg Volume2.00M
Market Cap96.84M
P/E Ratio—
EPS$-0.76
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+1,841.6% upside
Current
$1.85
$1.85
Target
$35.92
$35.92
$30.62
$35.92 avg
$44.24
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 70.94M | 26.85M | 24.30M |
| Net Income | 22.67M | 2.09M | 2.49M |
| Profit Margin | 32.0% | 7.8% | 10.3% |
| EBITDA | 13.02M | 3.87M | 3.57M |
| Free Cash Flow | — | 2.98M | 2.09M |
| Rev Growth | — | +10.3% | +9.4% |
| Debt/Equity | — | 0.41 | 0.35 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |